Research Article
Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana
Table 1
Visual inspection of packaging of artemether-lumefantrine fixed-dose combination medicines.
| | Sample code and dosage form | Labelled strength | No. of tablets per blister pack | Country of manufacture | Batch No. | Mfg. date | Exp. date | FDA/PML number |
| | LZT | | Tablet 1 | 20 mg/120 mg | 24 | Ghana | HIXO03 | 03/2022 | 03/2024 | Yes | | Tablet 2 | 20 mg/120 mg | 24 | Ghana | HIXO03 | 03/2022 | 03/2024 | Yes | | LNT | | Tablet 3 | 80 mg/480 mg | 6 | India | B1AFM016 | 02/2022 | 01/2025 | Yes | | Tablet 4 | 80 mg/480 mg | 6 | India | B1AFM016 | 02/2022 | 01/2025 | Yes | | Tablet 5 | 80 mg/480 mg | 6 | India | B1AFM016 | 02/2022 | 01/2025 | Yes | | Tablet 6 | 80 mg/480 mg | 6 | India | B1AFM030 | 04/2022 | 03/2025 | Yes | | Tablet 7 | 80 mg/480 mg | 6 | India | B1AFM030 | 04/2022 | 03/2025 | Yes | | Tablet 8 | 20 mg/120 mg | 24 | India | A1AFJO94 | 07/2021 | 06/2024 | Yes | | MLT | | Tablet 9 | 80 mg/480 mg | 6 | Ghana | 1711Y | 11/2022 | 11/2024 | No | | Tablet 10 | 80 mg/480 mg | 6 | Ghana | 1711Y | 11/2022 | 11/2024 | No | | Tablet 11 | 80 mg/480 mg | 6 | Ghana | 1711Y | 11/2022 | 11/2024 | No | | Tablet 12 | 80 mg/480 mg | 6 | Ghana | 1711Y | 11/2022 | 11/2024 | No | | Tablet 13 | 80 mg/480 mg | 12 | Ghana | 0503Y | 03/2022 | 03/2024 | No | | LFT | | Tablet 14 | 80 mg/480 mg | 6 | Ghana | T017F024 | 04/2022 | 03/2025 | Yes | | Tablet 15 | 80 mg/480 mg | 6 | Ghana | T017F024 | 04/2022 | 03/2025 | Yes | | Tablet 16 | 80 mg/480 mg | 6 | Ghana | T017F019 | 04/2022 | 03/2025 | Yes | | Tablet 17 | 80 mg/480 mg | 6 | Ghana | T017F050 | 12/2022 | 11/2025 | Yes | | Tablet 18 | 80 mg/480 mg | 6 | Ghana | T017F050 | 12/2022 | 11/2025 | Yes | | CTT | | Tablet 19 | 80 mg/480 mg | 6 | Turkey | KCU43 | 07/2021 | 06/2023 | Yes | | Tablet 20 | 80 mg/480 mg | 6 | Turkey | KDE81 | 09/2021 | 08/2023 | Yes | | Tablet 21 | 80 mg/480 mg | 6 | Turkey | KDE81 | 09/2021 | 08/2023 | Yes | | Tablet 22 | 80 mg/480 mg | 6 | Turkey | KDE81 | 09/2021 | 08/2023 | Yes | | TMT | | Tablet 23 | 80 mg/480 mg | 6 | Ghana | BN001 | 07/2021 | 07/2025 | Yes | | Tablet 24 | 80 mg/480 mg | 6 | Ghana | BN001 | 07/2021 | 07/2025 | Yes | | Tablet 25 | 80 mg/480 mg | 6 | Ghana | BN001 | 07/2021 | 07/2025 | Yes | | IDT | | Tablet 26 | 80 mg/480 mg | 6 | India | I-56001 | 01/2022 | 12/2024 | Yes | | Tablet 27 | 80 mg/480 mg | 6 | India | I-56001 | 01/2022 | 12/2024 | Yes | | DMT | | Tablet 28 | 80 mg/480 mg | 6 | India | LU22007 | 02/2022 | 01/2025 | Yes | | Tablet 29 | 80 mg/480 mg | 6 | India | LU22007 | 02/2022 | 01/2025 | Yes | | LNS | | Suspension-1 | 240 mg/1440 mg/5 ml | N/A | India | B1AFM020 | 03/2022 | 03/2024 | Yes | | Suspension-2 | 240 mg/1440 mg/5 ml | N/A | India | B1AFM020 | 03/2022 | 03/2024 | Yes | | MLS | | Suspension 3 | 20 mg/120 mg/5 ml | N/A | Ghana | 0701Z | 01/2023 | 12/2025 | Yes | | Suspension 4 | 20 mg/120 mg/5 ml | N/A | Ghana | 7308Y | 08/2022 | 08/2024 | Yes | | LFS | | Suspension 5 | 20 mg/120 mg/5 ml | N/A | Ghana | D003F094 | 09/2022 | 09/2025 | Yes | | Suspension 6 | 20 mg/120 mg/5 ml | N/A | Ghana | D003F094 | 09/2022 | 09/2025 | Yes | | IDS | | Suspension 7 | 20 mg/120 mg/5 ml | N/A | India | I-57001 | 01/2021 | 12/2023 | Yes | | Suspension 8 | 20 mg/120 mg/5 ml | N/A | India | I-57001 | 01/2021 | 12/2023 | Yes | | BMS | | Suspension 9 | 20 mg/120 mg/5 ml | N/A | India | PDS01-01 | 01/2023 | 01/2015 | Yes | | Suspension 10 | 20 mg/120 mg/5 ml | N/A | India | CDS09-02 | 01/2021 | 12/2023 | Yes | | STS | | Suspension 11 | 20 mg/120 mg/7 ml | N/A | India | 1390423 | 06/2021 | 06/2024 | Yes | | Suspension 12 | 20 mg/120 mg/7 ml | N/A | India | 1390423 | 06/2021 | 06/2024 | Yes |
|
|
N/A = not applicable. FDA = Food and Drugs Authority, Ghana. PML = product manufacturing license. Mfg. date = manufacturing date. Exp. date = expiry date.
|
